Clinical trial
Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL).
R. Palich
M. Lê
A. Castagna
C. Allavena
A. Antinori
D. Canetti
J. Tiraboschi
C. Duvivier
E. Martínez
P. Domingo
Salima Barkat
Y. Dudoit
L. Béniguel
G. Peytavin
Anne-Geneviève Marcelin
C. Soulié
L. Assoumou
Christine Katlama
Medicine